MECHANISM OF RESISTANCE TO TRASTUZUMAB (HERCEPTIN): AN OVERVIEW

Kabiru Labaran; Dr. Malami Dikko; Zayyanu Malami; Kabiru Musa Abdullahi; Mustafa Danrabi; Ahmad Zayyanu

doi:10.71146/kjmr327

Authors

Kabiru Labaran Sultan Abdurrahman College of Health Technology Gwadabawa, Sokoto State, Nigeria Author
Dr. Malami Dikko Sultan Abdurrahman College of Health Technology Gwadabawa, Sokoto State, Nigeria Author
Zayyanu Malami Sultan Abdurrahman College of Health Technology Gwadabawa, Sokoto State, Nigeria Author
Kabiru Musa Abdullahi Sultan Abdurrahman College of Health Technology Gwadabawa, Sokoto State, Nigeria Author
Mustafa Danrabi Sultan Abdurrahman College of Health Technology Gwadabawa, Sokoto State, Nigeria Author
Ahmad Zayyanu General Hospital Kware, Sokoto State, Nigeria Author

DOI:

https://doi.org/10.71146/kjmr327

Keywords:

Herceptin resistance, strategies to overcome resistance, signaling pathways, breast cancer, women, Trastuzumab

Abstract

This paper performs a comprehensive description of Trastuzumab resistance and possible remedy mechanism. Trastuzumab (Herceptin) is a monoclonal antibody used to treat HER-2 positive breast cancer. However, resistance to Herceptin is a significant clinical challenge. This review discusses the mechanisms of resistance to Herceptin, including increased activity of growth factor receptors, alterations in signaling cascades, and insulin-like growth factor receptor signaling. The role of PTEN loss, PI3K/AKT pathway activation, and HER-2 receptor truncation in Herceptin resistance is also explored. Strategies to overcome resistance, such as combining Herceptin with other therapies or targeting alternative signaling pathways, are discussed. Understanding the mechanisms of resistance to Herceptin is crucial for developing effective therapeutic strategies to improve patient outcomes.